Levi & Korsinsky Urges ARS Pharmaceuticals Investors to Act Before Securities Class Action Deadline Approaches
In a recent development impacting investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY), the law firm Levi & Korsinsky, LLP has issued a crucial reminder regarding a forthcoming securities class action. If you acquired shares of ARS Pharmaceuticals between March 9, 2026, and June 24, 2026, you may be eligible for recovery.
On June 24, 2026, shares of ARS dipped sharply after the company announced that no new commercial formulary additions had been made for its product, neffy, in the upcoming July 1 cycle. This news underscored the potential misrepresentation of the company's progress in negotiations with CVS Caremark, the final major pharmacy benefit manager (PBM) hindering broader access to neffy.
The securities class action is predicated on allegations that ARS Pharmaceuticals misled investors regarding its efforts to eliminate prior authorization requirements at CVS. The firm originally anticipated that approximately 93% of its commercial coverage would be accessible soon; however, only 57% of covered individuals could access neffy without those prior authorizations.
Joseph E. Levi, Esq. from Levi & Korsinsky emphasizes that investors were under the impression that the company was close to resolving the issues with CVS. However, the reality was that risks surrounding the CVS Caremark proposal were not adequately disclosed. The company failed to communicate the possibility that the decision could be delayed beyond the anticipated timeline, pushing any decisions into 2027 instead of the expected summer rollout.
As a consequence of the sudden lapse in the expected formulary updates, ARS shares plummeted by $2.52, marking a staggering decline of 23.9%. The lawsuit claims that the management's portrayal of CVS's approval process was overly optimistic and misaligned with the actual circumstances, prompting a legal investigation into the company's disclosure practices.
This class action also addresses other critical points regarding ARS’s lack of transparency. Investors may raise concerns about how nearly 43% of covered lives remained subject to the friction caused by prior authorizations, alongside the approval rates that hovered around 45% for submissions requiring authorization.
Potential participants in this class action must be aware of the deadline for lead plaintiff motions, set for October 5, 2026. This presents a pressing opportunity for affected investors to step forward and assert their rights. Levi & Korsinsky, with a track record of recovering substantial amounts for investors, is inviting those who purchased shares during the defined period to reach out for a complimentary evaluation of their case.
Key FAQs highlight that investors who sold their shares during this period, even if they no longer hold them, retain eligibility based on their purchase dates. No upfront fees are required for joining the class action; compensation is typically conditional on the successful outcome of the case.
With October 5 rapidly approaching, ARS Pharmaceuticals investors should act swiftly. Those wishing to qualify for recovery or seeking more information on their eligibility are encouraged to contact Levi & Korsinsky using the provided contacts for an immediate review of their situation.
This situation presents a salient case in shareholder rights litigation, reinforcing the importance of transparency and accurate information dissemination in the financial sector. As the class action unfolds, it will be crucial for affected investors to stay informed and participate actively in seeking justice for their financial losses.
On June 24, 2026, shares of ARS dipped sharply after the company announced that no new commercial formulary additions had been made for its product, neffy, in the upcoming July 1 cycle. This news underscored the potential misrepresentation of the company's progress in negotiations with CVS Caremark, the final major pharmacy benefit manager (PBM) hindering broader access to neffy.
The securities class action is predicated on allegations that ARS Pharmaceuticals misled investors regarding its efforts to eliminate prior authorization requirements at CVS. The firm originally anticipated that approximately 93% of its commercial coverage would be accessible soon; however, only 57% of covered individuals could access neffy without those prior authorizations.
Joseph E. Levi, Esq. from Levi & Korsinsky emphasizes that investors were under the impression that the company was close to resolving the issues with CVS. However, the reality was that risks surrounding the CVS Caremark proposal were not adequately disclosed. The company failed to communicate the possibility that the decision could be delayed beyond the anticipated timeline, pushing any decisions into 2027 instead of the expected summer rollout.
As a consequence of the sudden lapse in the expected formulary updates, ARS shares plummeted by $2.52, marking a staggering decline of 23.9%. The lawsuit claims that the management's portrayal of CVS's approval process was overly optimistic and misaligned with the actual circumstances, prompting a legal investigation into the company's disclosure practices.
This class action also addresses other critical points regarding ARS’s lack of transparency. Investors may raise concerns about how nearly 43% of covered lives remained subject to the friction caused by prior authorizations, alongside the approval rates that hovered around 45% for submissions requiring authorization.
Potential participants in this class action must be aware of the deadline for lead plaintiff motions, set for October 5, 2026. This presents a pressing opportunity for affected investors to step forward and assert their rights. Levi & Korsinsky, with a track record of recovering substantial amounts for investors, is inviting those who purchased shares during the defined period to reach out for a complimentary evaluation of their case.
Key FAQs highlight that investors who sold their shares during this period, even if they no longer hold them, retain eligibility based on their purchase dates. No upfront fees are required for joining the class action; compensation is typically conditional on the successful outcome of the case.
With October 5 rapidly approaching, ARS Pharmaceuticals investors should act swiftly. Those wishing to qualify for recovery or seeking more information on their eligibility are encouraged to contact Levi & Korsinsky using the provided contacts for an immediate review of their situation.
This situation presents a salient case in shareholder rights litigation, reinforcing the importance of transparency and accurate information dissemination in the financial sector. As the class action unfolds, it will be crucial for affected investors to stay informed and participate actively in seeking justice for their financial losses.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.